Innate Pharma (IPHA) Non-Current Debt (2017 - 2025)
Innate Pharma's (IPHA) quarterly Non-Current Debt came in at $16.0 million in Q4 2025, down 32.69% YoY from $23.8 million in Q4 2024, and down 21.74% on a QoQ basis from $20.5 million in Q2 2025.
Innate Pharma (IPHA) Non-Current Debt (2017 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 9 years of Non-Current Debt data on file, last reported at $16.0 million in Q4 2025.
- Quarterly Non-Current Debt fell 32.69% year-over-year to $16.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.0 million (down 32.69% YoY) and the FY2025 annual result came in at $26.3 million, down 20.67% from the prior year.
- Non-Current Debt declined to $16.0 million in Q4 2025, from $20.5 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $41.0 million in Q4 2022 to a low of $15.4 million in Q4 2021.
- A 5-year average of $26.9 million and a median of $26.2 million in 2024 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2021 — Non-Current Debt slumped 99.9% — and 2022, when it jumped 165.18%.
- Tracing IPHA's Non-Current Debt over 5 years: stood at $15.4 million in 2021, then jumped by 165.18% to $41.0 million in 2022, then decreased by 18.69% to $33.3 million in 2023, then decreased by 28.5% to $23.8 million in 2024, then sank by 32.69% to $16.0 million in 2025.
- The last three Non-Current Debt figures came in at $16.0 million (Q4 2025), $20.5 million (Q2 2025), and $23.8 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | 16.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.03 Mn |
| Jun 30, 2025 | 20.48 Mn |
| Dec 31, 2024 | 23.81 Mn |
| Jun 30, 2024 | 28.62 Mn |
| Dec 31, 2023 | 33.31 Mn |
| Jun 30, 2023 | 38.46 Mn |
| Dec 31, 2022 | 40.96 Mn |
| Jun 30, 2022 | 34.90 Mn |
| Dec 31, 2021 | 15.45 Mn |
| Jun 30, 2021 | 17.44 Mn |
| Dec 31, 2020 | 20.20 Mn |
| Jun 30, 2020 | 16.78 Bn |
| Dec 31, 2019 | 18.37 Mn |
| Dec 31, 2018 | 4.59 Mn |
| Dec 31, 2017 | 5.32 Mn |